A 2026 FAERS pharmacovigilance study of 28,938 dystonia reports found the strongest reporting signal for metoclopramide, while antipsychotics dominated the high-volume psychiatric medication signal and most timed cases began within 30 days of drug exposure.1 Research Highlights 28,938 dystonia reports: Chen et al. analyzed 27,618 patients represented in FAERS reports from Q1 2004 through Q3 …
A 2026 individual participant data meta-analysis of 1,721 dementia trial participants linked risperidone to cerebrovascular adverse events, HR 4.11 (95% CI 1.77 to 9.51), and major cardiovascular adverse events, HR 2.00 (95% CI 1.23 to 3.26).1 The timing signal is the practical warning: median first cerebrovascular event appeared at 4.3 weeks, and median first major …
Mukai et al.’s 499-person Phase 2b schizophrenia trial tested whether higher, sustained PDE10A inhibition could turn MK-8189 into a non-D2 antipsychotic; it did not. At week 6, MK-8189 missed the PANSS total endpoint at 16 mg (−2.8 points vs. placebo; 95% CI −8.3 to 2.6; P = 0.241) and 24 mg (−0.7 points; 95% CI …
The risperidone-stroke link in dementia is one of the longest-running safety signals in geriatric psychiatry, anchoring the FDA’s 2005 black-box warning on atypical antipsychotic mortality. Popular framing reduces it to “antipsychotics cause stroke in dementia” — a true sentence that flattens a multi-axis decision. Choma’s 2025 analysis of UK primary care records is the largest …
Social media has emerged as a pivotal source of real-world evidence, especially in understanding patient experiences and perceptions regarding the treatment of severe mental disorders such as Schizophrenia and related psychotic disorders (SRD) and Bipolar Disorder (BD). Leveraging advanced artificial intelligence (AI) techniques, a comprehensive analysis of 893,289 tweets between 2008 and 2022 revealed significant …
It is estimated that 40% of U.S. adults are obese – and this figure is projected to continue growing. One potential reason for weight gain and a possible catalyst for obesity is use of pharmaceutical drugs (i.e. medications). Medication-induced weight gain poses a significant challenge in healthcare, affecting both patient well-being and treatment adherence. Key …
Risperdal (Risperidone) is an atypical antipsychotic medication that has been approved since 1994 for the treatment of schizophrenia, bipolar disorder, as well as certain cases of autism. It functions as an antagonist of the neurotransmitter dopamine. By acting as an antagonist, it reduces overall dopamine activity in the brain and helps eliminate many of the …